Darren M. Brenner, MD

Experts talk about the impact of a collaborative and supportive patient-provider relationship in the management of IBS-C and CIC.

Thought leaders explore premature treatment discontinuation and some of the reasons leading to it, such as time to response and safety in regards to the use of prescription therapies for IBS-C and CIC.

Experts discuss the current use of OTC and review guidelines for prescription treatments for IBS-C and CIC.

Thought leaders review prevalence, common symptoms, and patient burden of IBS-C and CIC.